Get started

Healthcare

Biogen: Further GrowthAfter the stock price touched new highs in October 2019 ( management confirmed rebooting of aducanumab's development), Biogen started a consolidation phase. I plotted the Ichimoku Cloud on a daily chart, together with the Bollinger bands, to highlight the volatility and confirm the consolidation phase. Currently, from a technical point of view, we are in an exciting phase, testing the high line of the cloud with a bullish configuration, as also confirmed by the Stochastic. The upward trend is also confirmed by fundamental analysis. Biogen counts on a strong collaboration with Roche in oncology, and on growing revenues thanks to Ocrevus (Multiple Sclerosis), as well as to a significant pipeline. Furthermore, the complexity of Biogen's drugs makes the production of Biosimilars difficult. Disclosure: My articles contain statements and projections based on assumptions on capital markets, and therefore inherently subject to numerous risks and uncertainties. Before buying or selling any stock you should do your own research and reach your own conclusion or consult a financial advisor. Investing includes risks, including loss of principal. I am not a financial advisor
NASDAQ:BIIBLong
by Investing_Fellow
MYL - Worth Keeping on a Watch ListThe weekly chart for Mylan has broken out from a bearish trendline this week. We can see from the VPVR that there is not much volume resistance at these prices either. There is also a bullish divergence on the RSI. Relative strength has begun to improve too. The price still needs to clear both a 50-EMA & 200-EMA & bulls would want to see a golden cross occur in the future. A lot of hurdles left for this stock to get over but this may be a name worth keeping on a watch list at least.
MLong
by Chartimistic
HIIQ an undervalued growth stock in a sector with political riskHIIQ was already undervalued, with a forward P/E of 4.65, but it just got even moreso today as analysts bumped its earnings forecast by roughly 20%. This is a low-volume stock, so the market hasn't yet noticed or reacted to the upgrade except for a few options traders. The main problem with HIIQ is that health insurance stocks face a lot of political risk going into an election year when the Democratic candidates may be inclined to try to kill this industry altogether.
HLong
by ChristopherCarrollSmith
Convatec - Chronically undervalued?Buy Convatec (CTEC.L) ConvaTec Group PLC is a United Kingdom-based medical product and technology company. The Company focuses on therapies for the management of chronic conditions, including products used for advanced chronic and acute wound care, ostomy care, continence and critical care and infusion devices used in the treatment of diabetes and other conditions. Market Cap: £3.79Billion The recovery over the medium term continues as the shares trade in a sequence of higher highs and higher lows. The recent corrective move back to the trend line has attracted some buying interest. The formation and break of a small wedge is also an encouraging sign that we can expect a continuation. There is an unfilled gap at 223p to target on the upside. Stop: 181.6p Target 1: 211p Target 2: 222p Target 3: 240p Interested in UK Stocks? Join our free Telegram channel for up to date analysis on the best main market opportunities in the UK right now - t.me
LSE:CTECLong
by Investamate
CVS moment of truth is comingCVS has been headed toward the top of its parallel channel. It's currently overbought, so its first test of the channel top may get rejected. However, expect a breakout soon after. CVS is my favorite investment thesis in the entire market right now. The company is opening 1500 HealthHub stores by the end of 2021 and is also completing a merger with Aetna. Its earnings are expected to grow, and the stock is absurdly undervalued. Fair value based on forward P/E for 2021 is something like $95 per share. Even based on this year's P/E, it should be at least $79. (I base these numbers on the Zack's "Price and Consensus" chart, which is one of my favorite tools for fundamental analysis. We'll do an educational episode on this on the "Wall Street Petting Zoo" Youtube channel next week.)
NYSE:CVSLong
by ChristopherCarrollSmith
Harrow may bounce on lawsuit newsBack in May, a jury ruled in Harrow Health's favor in a lawsuit that Allergan filed against Harrow for intellectual property infringement. Allergan has been appealing the ruling, but today the two companies jointly filed an 8k form indicating that they had jointly dismissed all pending appeals and exchanged no money. In other words, Harrow got off scot-free and will no longer incur legal fees related to the case. This is great news, so it's surprising that the stock is down, especially when the market as a whole is up. Perhaps Harrow will get a boost if some news agencies pick up the story. In the meantime, Harrow is approaching support at about $5. I picked up a few shares at $5.25 and will look to buy more at $5. Harrow Health has a 9.4/10 Equity StarMine Summary Score and is rated undervalued (73/100) by S&P Capital IQ.
NASDAQ:HROWLong
by ChristopherCarrollSmith
$VIVE Classic "Cursed After Reversed" Or Can It ReVIVE Itself?VIVE seems like it can't get out of its own way. Great gap up in the morning but yet again, another red close. Even after reversing, shares are back at penny stock levels. So is it doomed to repeat history or can it find a new bottom? I don't know if anyone really knows for sure just yet. "Viveve’s stock price had a terrible September, dropping more than 57%. However, its start to October is looked promising at the start. The healthcare penny stock gapped up over 25% during premarket hours on October 1st. In addition, the penny stock has already tripled its average trading volume. But as you see, VIVE stock has pulled back considerably from those premarket highs."* *Quote Source: 5 Money Making Penny Stocks To Watch This Week Most Recent News: Viveve Raises $6.76 million Through Completion of At-The-Market Equity Financing ENGLEWOOD, CO / ACCESSWIRE / October 1, 2019 / Viveve Medical, Inc. (VIVE), a medical technology company focused on women's intimate health, today announced the completion of its at-the-market (ATM) offering of $6.76 million of shares of its common stock with Ladenburg Thalmann & Co. Inc. as the sales agent. The company sold 1,004,171 shares at a weighted average price of $6.73 per share (adjusting for a reverse stock split of Viveve common stock effected September 18, 2019) resulting in net proceeds of approximately $6.56 million to the company after deduction of sales commissions. As of September 30, 2019, the company had 1,469,589 shares outstanding. About VIVE Viveve Medical, Inc. is a medical technology company focused on women's intimate health. Viveve is committed to advancing new solutions to improve women's overall well-being and quality of life. The internationally patented Viveve® System incorporates cryogen-cooled monopolar radiofrequency (CMRF) technology to uniformly deliver volumetric heating while gently cooling surface tissue to generate neocollagenesis in a single in-office session. News Source: finance.yahoo.com
V
by PennyStocks101
1
Why Is KSHB Going Up While Most Pot Stocks Are Getting Slammed?KSHB has been one of just a fine few pot stock related names that has actually gone up. So what's the deal? The company’s stock price struggled throughout September, decreasing 60% on a massive drop during trading hours on September 26th. This was due to the company announcing a direct offering for shares at $1.75 per. This cannabis company is comprised of several industry-leading companies. This includes one of the largest producers of vaporizer products and packaging, Kush Supply Co. Furthermore, it owns Kush Energy which provides hydrocarbon gases and solvents to the cannabis sector. "The direct offering was valued at $30.2 million and is expected to close relatively soon. Investors must have found this offering promising because today, on October 1st, the marijuana stock is up 11%. Could this lead to a strong and promising October for investors after that rough September?"* *Quote Source: 5 Penny Stocks To Watch This Week Stock: KSHB
K
by PennyStocks101